<< Mitteilung

2019-10-21 22:15

GENFIT: Combined Shareholders’ Meeting of November 27, 2019 – Availability of Preparatory Documents

GENFIT: Combined Shareholders’ Meeting of November 27, 2019 – Availability of Preparatory Documents

Lille (France), Cambridge (Massachusetts, United States), October 21, 2019 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced that it published in October 21, 2019’s French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Combined Shareholders’ Meeting to be held on Wednesday, November 27 2019, at 2:30pm, at the Company’s headquarters, located Parc Eurasanté, 885 avenue Eugène Avinée in Loos (59120), France.

Management will provide an update on the Company’s activities over the last few months.

All documentation regarding this Shareholders’ Meeting is available to shareholders in accordance with existing regulations, and is available on the Company’s website, in the documentation center (https://ir.genfit.com/financial-information/shareholders-meeting).

Documents listed in Article R.225-83 of the French commercial code are available to shareholders in accordance with existing regulations.

For this Shareholders’ Meeting, the Company will allow shareholders to send their voting instructions via Internet through the VOTACCESS platform. A tutorial to familiarize shareholders with this new tool for online voting is available in the documentation center.

Shareholders are invited to contact the toll-free (France only) number starting Tuesday, October 22, 2019, with any questions regarding how to participate in the Meeting: 0800 940 651.

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for NASH, and GENFIT plans to initiate a Phase 3 clinical trial in PBC later this year following its positive Phase 2 results. As part of GENFIT’s comprehensive approach to clinical management of NASH patients, the company is also developing a new, non-invasive and easy-to-access blood-based in vitro diagnostic test to identify patients with NASH who may be appropriate candidates for drug therapy. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 160 employees. GENFIT is a public company listed on the Nasdaq Global Select Market and in compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com

GENFIT | Investors

Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com

PRESS RELATIONS | Media

Hélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com

  GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com       

Attachment

Indizes

LU0916829079 641.1759 (-1.10%)

Aktien und Anleihen

Aktie Kurs Letz. +/-
Aperam (EUR) 27.63 27.55 +0.29%
ArcelorMittal (EUR) 14.92 15.208 -1.89%
BlueMarHoldings (EUR) 3.7 3.5 +5.71%
Brederode (EUR) 70.4 70.6 -0.28%
EDIFY act. ord. (EUR) 55.0 55.0 +0.00%
HellaGmbHKGaa (EUR) 47.96 48.14 -0.37%
ImmoLux-Airport (EUR) 7.75 9.55 -18.85%
Luxempart (EUR) 54.0 54.0 +0.00%
RTLGroup (EUR) 43.76 43.46 +0.69%
ReinetInvest (EUR) 16.5 16.5 +0.00%
SEO .prvB (EUR) 228.0 240.0 -5.00%
SEO 1/5prvB (EUR) 49.4 52.0 -5.00%
SES FDR (EUR) 14.075 14.45 -2.60%
SocFinCaoutchcs (EUR) 25.8 25.8 +0.00%
Socfinaf (EUR) 11.2 11.3 -0.89%
Socfinasia (EUR) 13.8 13.8 +0.00%
Vonovia (EUR) 47.01 46.55 +0.99%
Anleihe Kurs Letz. +/-
AXA 5,25% 16/04/2040 (EUR) 102.129 102.179 -0.05%
AirbusFinan 2,375% 02/04/2024 (EUR) 109.69 109.629 +0.06%
Astaldi 7,125% 01/12/2020 (EUR) 19.121 19.282 -0.83%
BASF 2,5% 22/01/2024 (EUR) 110.092 110.04 +0.05%
BNGBank 4,375% 16/02/2021 (USD) 103.133 103.138 -0.00%
BarclaysBank 4,75% pp (EUR) 99.019 99.013 +0.01%
Bayer 1,875% 25/01/2021 (EUR) 101.93 101.94 -0.01%
Bayer 2,375% 02/04/2075 (EUR) 101.515 101.555 -0.04%
Bekaert 5% 06/12/2019 (EUR) 100.252 100.273 -0.02%
BenOldmanESB 10% 23/10/2021 (EUR) 102.0 102.0 +0.00%
Bombardier 6,125% 15/05/2021 (EUR) 104.105 104.12 -0.01%
Bouygues 3,625% 16/01/2023 (EUR) 112.192 112.191 +0.00%
CasinoGuichardP FRN pp (EUR) 38.266 39.13 -2.21%
CmaCgm 7,75% 15/01/2021 Reg S (EUR) 90.426 90.6 -0.19%
Colombia 8,375% 15/02/2027 (USD) 123.3 123.0 +0.24%
Daimler 2% 25/06/2021 (EUR) 103.34 103.365 -0.02%
DeutscheBank 2% 02/12/2019 (USD) 96.78 96.75 +0.03%
DeutscheBank 2,2% 17/11/2020 (USD) 98.6 98.58 +0.02%
DtscheLufthansa 5,125% 12/08/2075 (EUR) 105.675 106.15 -0.45%
EFSF 1,875% 23/05/2023 (EUR) 108.09 108.08 +0.01%
EFSF 2,25% 05/09/2022 (EUR) 107.71 107.71 +0.00%
ENI 1,75% 18/01/2024 (EUR) 107.25 107.2 +0.05%
GazCapital 8,625% 28/04/2034 (USD) 144.685 145.0 -0.22%
GiePsaTresor 6% 19/09/2033 (EUR) 147.015 146.37 +0.44%
HeidelbergFinLu 7,5% 03/04/2020 (EUR) 102.875 102.93 -0.05%
HornbachBau 3,875% 15/02/2020 (EUR) 100.934 100.947 -0.01%
KfWA 2% 02/05/2025 (USD) 101.53 101.22 +0.31%
Lafarge 4,75% 23/03/2020 (EUR) 101.64 101.68 -0.04%
Luxembourg 2,125% 10/07/2023 (EUR) 109.705 109.654 +0.05%
Luxembourg 2,25% 19/03/2028 (EUR) 120.603 120.461 +0.12%
Luxembourg 2,25% 21/03/2022 (EUR) 106.85 106.86 -0.01%
Luxembourg 2,75% 20/08/2043 (EUR) 143.669 141.305 +1.67%
Luxembourg 3,375% 18/05/2020 (EUR) 101.94 101.98 -0.04%
MOBY 7,75% 15/02/2023 Reg S (EUR) 35.328 35.361 -0.09%
McDonalds 2% 01/06/2023 (EUR) 107.429 107.403 +0.02%
MüchenerRückGes 6% 26/05/2041 (EUR) 109.011 109.047 -0.03%
NBFinanceLtd FRN 07/02/2035 (EUR) 93.426 93.5 -0.08%
NordRheinWFalen 2,375% 16/09/2021 (USD) 101.041 101.028 +0.01%
NovoBanco 100 09/04/2052 (EUR) 23.123 23.126 -0.01%
NovoBanco 3,5% 02/01/2043 (EUR) 98.398 98.46 -0.06%
OMV 6,25% pp (EUR) 127.475 127.465 +0.01%
Pemex 6,5% 02/06/2041 (USD) 97.594 97.478 +0.12%
PetroVenezuela 12,75% 17/02/2022 (USD) 28.7 27.0 +6.30%
PetroVenezuela 5,375% 12/04/2027 (USD) 13.933 13.933 +0.00%
PetroVenezuela 5,5% 12/04/2037 (USD) 13.93 13.93 +0.00%
Philippines 4,2% 21/01/2024 (USD) 107.797 107.795 +0.00%
Portugal 5,125% 15/10/2024 (USD) 113.192 113.072 +0.11%
RWE 3,5% 21/04/2075 (EUR) 109.905 109.965 -0.05%
RWE 6,625% 30/07/2075 (USD) 113.722 113.79 -0.06%
RaiffeisenBkInt 6% 16/10/2023 (EUR) 120.666 120.693 -0.02%
RussianFed 7,5% 31/03/2030 (USD) 120.594 120.558 +0.03%
SNCFMobilites 4,875% 12/06/2023 (EUR) 118.706 118.688 +0.02%
Sanofi 1,75% 10/09/2026 (EUR) 111.97 111.795 +0.16%
StadaArzneimitt 1,75% 08/04/2022 (EUR) 102.365 102.359 +0.01%
SüdzuckIntlFin FRN pp (EUR) 79.435 79.28 +0.20%
TelecomItaliaCa 7,2% 18/07/2036 (USD) 116.835 116.863 -0.02%
TelecomItaliaFi 7,75% 24/01/2033 (EUR) 147.341 147.656 -0.21%
Thyssenkrupp 2,5% 25/02/2025 (EUR) 103.135 103.324 -0.18%
Turkey 7,375% 05/02/2025 (USD) 108.542 108.254 +0.27%
VWIntlFin 4,625% pp (EUR) 111.935 111.87 +0.06%
VWIntlFin 5,125% pp (EUR) 112.73 112.715 +0.01%
Venezuela 11,75% 21/10/2026 (USD) 17.457 19.685 -11.32%
VeoliaEnvironn 6,125% 25/11/2033 (EUR) 171.295 170.818 +0.28%
YPF 8,5% 28/07/2025 Reg S (USD) 78.585 79.232 -0.82%
ØRSTED A/S 6,25% 26/06/3013 (EUR) 117.82 117.89 -0.06%